Open Access
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
J. M Oss,W Ojciech Z Areba,W. J Ackson,H Elmut K Lein,D Avid J. W Ilber,D Avid S. C Annom,J Ames,P. D Aubert,S Teven L. H Iggins,M Ary W. B Rown,M Ark L. A Ndrews +10 more
TLDR
In this article, the authors evaluated the effect of implantable defibrillator on survival in patients with a prior myocardial infarction and a left ventricular ejection fraction of 0.30 or less.Abstract:
A BSTRACT Background Patients with reduced left ventricular function after myocardial infarction are at risk for lifethreatening ventricular arrhythmias. This randomized trial was designed to evaluate the effect of an implantable defibrillator on survival in such patients. Methods Over the course of four years, we enrolled 1232 patients with a prior myocardial infarction and a left ventricular ejection fraction of 0.30 or less. Patients were randomly assigned in a 3:2 ratio to receive an implantable defibrillator (742 patients) or conventional medical therapy (490 patients). Invasive electrophysiological testing for risk stratification was not required. Death from any cause was the end point. Results The clinical characteristics at base line and the prevalence of medication use at the time of the last follow-up visit were similar in the two treatment groups. During an average follow-up of 20 months, the mortality rates were 19.8 percent in the conventional-therapy group and 14.2 percent in the defibrillator group. The hazard ratio for the risk of death from any cause in the defibrillator group as compared with the conventional-therapy group was 0.69 (95 percent confidence interval, 0.51 to 0.93; P=0.016). The effect of defibrillator therapy on survival was similar in subgroup analyses stratified according to age, sex, ejection fraction, New York Heart Association class, and the QRS interval. Conclusions In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy. (N Engl J Med 2002;346:877-83.)read more
Citations
More filters
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
Patrick T. O'Gara,Frederick G. Kushner,Deborah D. Ascheim,Donald E. Casey,Mina K. Chung,James A. de Lemos,Steven M. Ettinger,James C. Fang,Francis M. Fesmire,Barry A. Franklin,Christopher B. Granger,Harlan M. Krumholz,Jane A. Linderbaum,David A. Morrow,L. Kristin Newby,Joseph P. Ornato,Narith N. Ou,Martha J. Radford,Jacqueline E. Tamis-Holland,Carl L. Tommaso,Cynthia M. Tracy,Y. Joseph Woo,David Zhao +22 more
TL;DR: The 2017-18 FAHA/FACC/FAHA Education and Research Grants will be focused on advancing the profession’s understanding of central nervous system disorders and the management of post-traumatic stress disorder.
Journal ArticleDOI
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Sharon A. Hunt,William T. Abraham,Marshall H. Chin,Arthur M. Feldman,Gary S. Francis,Theodore G. Ganiats,Mariell Jessup,Marvin A. Konstam,Donna Mancini,Keith Michl,John A. Oates,Peter S. Rahko,Marc A. Silver,Lynne W. Stevenson,Clyde W. Yancy +14 more
TL;DR: Theodore G. Feldman, MD, PhD, FACC, FAHA, Chair as mentioned in this paper, Chair, Chair of FAHA 2015, 2016, 2017, 2018, 2019, 2019
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: The medical profession should play a central role in evaluating the evidence related to drugs, according to a report by the World Health Organization and the European Medicines Agency.
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
Patrick T. O'Gara,Frederick G. Kushner,Deborah D. Ascheim,Donald E. Casey,Mina K. Chung,James A. de Lemos,Steven M. Ettinger,James C. Fang,Francis M. Fesmire,Barry A. Franklin,Christopher B. Granger,Harlan M. Krumholz,Jane A. Linderbaum,David A. Morrow,L. Kristin Newby,Joseph P. Ornato,Narith N. Ou,Martha J. Radford,Jacqueline E. Tamis-Holland,Carl L. Tommaso,Cynthia M. Tracy,Y. Joseph Woo,David Zhao +22 more
TL;DR: This guideline makes more liberal use of summary recommendation tables (with references that support LOE) to serve as a quick reference (e.g. in PubMed), and more liberalUse of summaryRecommendations.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
Arthur J. Moss,W. Jackson Hall,David S. Cannom,James P. Daubert,Steven L. Higgins,Helmut U. Klein,Joseph H. Levine,Sanjeev Saksena,Albert L. Waldo,David J. Wilber,Mary W. Brown,Moonseong Heo +11 more
TL;DR: In this article, the authors studied whether prophylactic therapy with an implanted cardioverter-defibrillator, as compared with conventional medical therapy, would improve survival in this high-risk group of patients.
Journal ArticleDOI
A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease
Alfred E. Buxton,Kerry L. Lee,John D. Fisher,Mark E. Josephson,Eric N. Prystowsky,Gail E. Hafley +5 more
TL;DR: Electrophysiologically guided antiarrhythmic therapy with implantable defibrillators, but not with antiarrHythmic drugs, reduces the risk of sudden death in high-risk patients with coronary disease and asymptomatic, unsustained ventricular tachycardia.
Book
The Design and Analysis of Sequential Clinical Trials
TL;DR: This paper presents alternative Approaches to the Design and Analysis of Sequential Clinical Trials, and some examples of implementation ofSequential Methods: Some Examples.